Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 17/20 | 0.83 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.68 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.68 |
| ▸ | PIK3R1 | P27986 | 12/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2953967 | 0.91 | PIK3CB (0.70) | PIK3CBPIK3CAPIK3CDPIK3R1 | |
| SCHEMBL3566232 | 0.91 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3R1 | |
| SCHEMBL3567196 | 0.90 | PIK3CB (0.68) | PIK3CBPIK3CAPIK3CDPIK3R1 | |
| SCHEMBL3567200 | 0.90 | PIK3CB (0.68) | PIK3CBPIK3CAPIK3CDPIK3R1 | |
| SCHEMBL3567201 | 0.90 | PIK3CB (0.68) | PIK3CBPIK3CAPIK3CDPIK3R1 | |
| SCHEMBL3568141 | 0.89 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3R1 | |
| SCHEMBL15029769 | 0.89 | PIK3CB (0.68) | PIK3CBPIK3CAPIK3CDPIK3R1 | |
| SCHEMBL2817385 | 0.87 | PIK3CB (0.84) | PIK3CBPIK3CAPIK3CDPIK3R1 | |
| SCHEMBL15029293 | 0.87 | PIK3CB (0.66) | PIK3CBPIK3CAPIK3CDPIK3R1 | |
| SCHEMBL909603 | 0.86 | PIK3CB (0.90) | PIK3CBPIK3CAPIK3CDPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1741714-B1 | HETEROCYCLIC COMPOUND AND ANTI-MALIGNANT-TUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 2013-01-09 | — | — | EP | disclosed |
| US-7855199-B2 | antitumor agents such as 2-(2-difluoromethyl-4-methoxybenzimidazol-1 -yl)-4-(cis-2,6-dimethylmorpholino)-6-morpholinopyrimidine, used for inhibiting the growth of a human colon cancer cell, a human lung cancer cell, a human breast cancer cell or a human prostate cancer cell | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20080287431-A1 | Heterocyclic Compound and Anti-Malignant-Tumor Agent Containing the Same as Active Ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2008-11-20 | — | — | US | disclosed |
| EP-1741714-A1 | HETEROCYCLIC COMPOUND AND ANTI-MALIGNANT-TUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287431-A1 | Heterocyclic Compound and Anti-Malignant-Tumor Agent Containing the Same as Active Ingredient | TP53, RB1, VHL | PIK3CB 1564/4885PIK3CA 1466/4885PIK3CD 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.